Axonics Inc (OQ:AXNX)
Business Focus: Medical Devices & Implants
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 26 Technology Drive IRVINE CA 92618 |
| Tel: | N/A |
| Website: | https://www.axonics.com |
| IR: | See website |
| Key People | ||
| Raymond Wayne Cohen Chief Executive Officer, Director | Kari Keese Chief Financial Officer | Rinda K. Sama Chief Operating Officer |
| John Woock Executive Vice President, Chief Marketing and Strategy Officer | Alfred J. Ford Chief Commercial Officer | Karen L. Noblett Chief Medical Officer |
| Business Overview |
| Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Axonics Inc revenues increased 34% to $366.4M. Net loss decreased 90% to $6.1M. Revenues reflect United States segment increase of 55% to $343.9M. Lower net loss reflects Acquisition-related costs decrease of 74% to $5.9M (expense), Interest and other income increase from $5.1M to $16.7M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.28 to -$0.12. |
| Employees: | 797 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $3,045M as of Dec 31, 2023 |
| Annual revenue (TTM): | $366.38M as of Dec 31, 2023 |
| EBITDA (TTM): | $7.75M as of Dec 31, 2023 |
| Net annual income (TTM): | -$6.09M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$5.57M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 51,003,429 as of Feb 26, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.